🇺🇸

US SEC Filing Intelligence

· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 05, 2026

Cumulus Media Inc., the sole filing in this Bankruptcy & Insolvency intelligence stream, announced a prepackaged Chapter 11 plan of reorganization, highlighting severe liquidity pressures and a declining broadcast radio industry with no quantified operational improvements. Key creditors holding 72.05% of 2029 Secured Debt Claims have committed support via a Restructuring Support Agreement, signaling likely plan confirmation but underscoring deep financial distress. The debtors' board strongly recommends acceptance by the April 7, 2026 voting deadline, yet equity holders face probable wipeout or severe dilution in this negative sentiment (10/10 materiality) scenario. No period-over-period financial trends, insider trading, or capital allocation details were quantified, but ongoing industry decline points to structural headwinds. Market implications include heightened volatility for CUMULUS MEDIA INC (CMLS) equity, potential short opportunities, and distressed debt plays ahead of case commencement.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 05, 2026

Across 34 US SEC filings dated March 5, 2026, focused on board room changes, a dominant theme is proactive board refreshments and C-suite transitions, with 18 positive sentiment announcements (e.g., expert director additions at AZZ, Janus, PacBio) signaling strategic enhancement amid growth strategies. Neutral sentiments prevail in 13 cases involving retirements/planned successions (e.g., Cardinal Health CAO retire Feb 2027, McKesson CFO May 2026), minimizing disruption, while 2 negative/mixed cases highlight risks (Match Group COO elimination, Sysco CFO to Fortune 10). Sparse but positive period trends include PACS revenue +29.3% YoY to $5.29B, Sysco FY25 sales >$81B with FY26 EPS guidance reaffirmed at high-end $4.50-$4.60, and WEBTOON 160M MAUs. Forward-looking catalysts cluster in Q2 2026 (multiple effective dates), with comp plans tying awards to EBITDA/ROIC/TSR (e.g., Invitation Homes NOI CAGR targets to 2028). Portfolio-level: High talent mobility (e.g., Kenny Cheung Sysco to McKesson), board independence rising (AZZ 7/8 independent), implying sector confidence but CFO/CAO churn (9 instances) warrants monitoring for execution risks. Actionable: Favor healthcare/tech with deep benches (Delta, SentinelOne), avoid abrupt terminations (Trulieve, Match).

34 high priority 34 total filings
· daily

US Merger & Acquisition SEC Filings — March 05, 2026

The USA M&A & Takeover Activity stream reveals a surge in SPAC activity with 8 out of 12 filings tied to blank check companies, including IPOs raising over $1.1B collectively (Averin $284M, Fortress $250M, TRG $200M, Kensington $200M, GalaxyEdge $100M), extensions (Athena), and unit separations (OneIM), signaling robust dealflow targeting tech, AI, quantum, LatAm, automotive/defense/energy. Actual M&A highlights include Pasqal's $2B SPAC merger with Bleichroeder offering $600M proceeds amid 100% 2025 revenue growth, and T Stamp's acquisition of Lexverify for LLM expertise. Camp4 Therapeutics reported mixed FY2025 results with revenue exploding 437% YoY to $3.5M and cash runway to 2028, but net loss widened 55% YoY to $80.4M due to non-cash charges. Period-over-period trends show strong fundraising momentum but pockets of financial strain like Fortress's $13.2M shareholders' deficit post-IPO and Invest's material weaknesses in controls. Portfolio-level patterns indicate heightened M&A appetite in quantum computing, biotech, and AI, with H2 2026 catalysts from closings and trials; implications favor long SPAC proxies and targets ahead of redemptions.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 05, 2026

Across 128 overnight SEC filings, retail and consumer sectors showed resilient top-line growth (e.g., Burlington +11% YoY sales, BJ's +5.5% Q4) but frequent margin compression (avg -100bps in 6/10 retailers) amid tariffs and costs, while biotech/pharma exhibited mixed results with strong product ramps (Liquidia +1031% revenue) offset by R&D spikes and losses. Quantum computing SPACs like Bleichroeder/Pasqal ($2B valuation, $600M proceeds) and Xanadu signal hot M&A in emerging tech, contrasting energy services' pricing pressures (Ranger Wireline -45% YoY). Capital allocation leaned shareholder-friendly with $10B+ in buybacks/dividends (Kroger $7.5B+$2B, EPAM $300M ASR, Ranger FCF >40% to repurchases/dividends). Guidance trends modest for 2026 (e.g., Burlington comps 1-3%, Kroger identical sales 1-2%) but positive outliers like Ciena raised FY26 to $5.9-6.3B (+28%). Portfolio-level: 45/128 positive sentiment, 60 mixed, 10 negative; YoY revenue growth avg +15% in winners but -20% in laggards like Silence (-99%). Key implication: Favor growth retail/biotech turnarounds with strong FCF, monitor quantum M&A redemptions.

65 high priority 63 medium 128 total filings
· daily

Biotech Small-Cap Approvals — March 04, 2026

Biotech small-cap approvals in this period featured 5 neutral generic ANDA/NDA entries, signaling routine portfolio expansion for sponsors like Apotex, Almatica, Macleods, Humanwell, and Anthea amid pricing and competition risks. The sole high-impact event was Ascendis Pharma's NAVEPEGRITIDE approval (NME, Priority Review, Orphan), a bullish catalyst with premium pricing potential despite unspecified indication. Overall, 83% neutral signals highlight limited innovation, constraining sector-wide conviction without market size details.

6 total filings
· daily

Big Pharma Approvals — March 04, 2026

This period yields four neutral signals from Big Pharma approvals, with only Janssen's PREZCOBIX (darunavir/cobicistat) providing substantive details on a standard-review original NDA approved 2026-02-27. Three identical, empty records for Novo Nordisk's SOMAPACITAN-BECO represent 75% concentration but offer zero insights, signaling potential data gaps. No bullish/bearish catalysts emerge; monitor for label clarity to assess portfolio impact.

4 total filings
· daily

Orphan Drug Approvals — March 04, 2026

Two Priority Review orphan drug approvals on 2026-02-27 deliver bullish catalysts for Ascendis Pharma and BioMarin Pharm, with NME status for Ascendis' NAVEPEGRITIDE and efficacy supplement for BioMarin's PEGVALIASE-PQPZ. Orphan designations across both enable 7-year market exclusivity and premium pricing in rare disease markets. Unspecified indications cap addressable market visibility, warranting caution on revenue potential.

2 total filings
· daily

New Drug Approvals (Original) — March 04, 2026

This one-day snapshot reveals 7 FDA approvals dominated by 4 routine ANDA generics (Apotex, Macleods, Humanwell, Anthea) with neutral implications due to pricing pressures and unspecified markets. A single high-impact bullish signal emerges from Ascendis Pharma's NME-priority-orphan approval for NAVEPEGRITIDE (YUVIWEL), signaling premium pricing potential and biotech upside. Overall neutral period for institutional portfolios, with limited sector visibility absent therapeutic details.

7 total filings
· daily

DHS Homeland Security Contracts — March 04, 2026

DHS awarded $2.29B in contracts dominated by a $2.08B Coast Guard FRC shipbuilding obligation to Bollinger Shipyards, signaling multi-year commitment to complete a 58-cutter fleet by 2028. Smaller $105M and $105M awards to Birdon and BCCG highlight long-term ship repair (to 2034) and near-term border barrier construction. Bullish for shipbuilding sector (NAICS 336611) with 96% of value, amid low initial outlays across all.

3 total filings
· daily

Federal Construction & Infrastructure Contracts — March 04, 2026

Two major federal construction contracts totaling $511.2M under NAICS 236220 signal strong demand for institutional buildings, with Brasfield & Gorrie LLC showing $383M progressed execution on a $407M DOJ/FBI project and BCCG JV securing a fully obligated $104.7M DHS/CBP border barrier award. Both firm-fixed-price delivery orders, awarded via full/open competition to non-small businesses, highlight momentum in secure federal infrastructure through 2026. Investors should prioritize these contractors for revenue visibility while monitoring cost overrun risks.

2 total filings
· daily

New Federal Contractors — March 04, 2026

This one-day snapshot reveals $3.84B in new federal contract records, with 54% ($2.08B) concentrated in DHS Coast Guard shipbuilding awards to Bollinger Shipyards, signaling multi-year maritime fleet expansion to 58 FRCs. Six bullish signals dominate across shipbuilding, construction, and IT services, driven by full/open competition wins, while HHS scientific services remain neutral. Investors should prioritize DHS-exposed defense industrials and monitor low initial outlays ($0-$10M on three contracts >$100M) for execution risks.

7 total filings
· daily

Significant Contract Modifications ($10M+) — March 04, 2026

DHS dominates with $2.3B+ in shipbuilding and border infrastructure mods, signaling sustained homeland security spending through 2034. Six bullish signals across $3.8B total value highlight revenue stability for contractors in shipbuilding, construction, and federal IT/health services. Neutral ATCC contract underscores nonprofit stability in CDC funding, but fixed-price risks warrant caution in construction-heavy awards.

7 total filings
· daily

Contract Deobligations Alert — March 04, 2026

DHS dominates with $2.3B+ in multi-year shipbuilding and border construction contracts, signaling sustained homeland security spending through 2034. Six bullish signals highlight revenue visibility for prime contractors amid low initial outlays, positioning defense and construction firms for growth. Neutral HHS nonprofit award underscores stable but non-equity scientific funding, with total obligations at $3.84B indicating robust federal commitments.

7 total filings
· daily

Contract Option Exercises — March 04, 2026

DHS commands 60%+ of $3.84B total obligations via massive shipbuilding (Bollinger $2.08B, Birdon $106M) and border construction (BCCG $105M) awards, signaling multi-year homeland security capex acceleration through 2034. Six bullish signals dominate across defense manufacturing, construction, and IT/services, with unexercised options adding $500M+ upside potential. Neutral nonprofit HHS award provides minor offset but underscores steady scientific funding amid fixed-price execution risks.

7 total filings
· daily

All HHS Contracts — March 04, 2026

HHS deployed $337M in stable funding for CDC reagent supply and CMS Medicare appeals processing, affirming long-term commitment to public health infrastructure through 2026-2029. Bullish for for-profit Maximus with $104M firm-fixed revenue and $17.5M runway; neutral for nonprofit ATCC's $233M cost-plus contract with $257M options upside. Cross-pattern: full/open competition favors established vendors in scientific/admin services, signaling sector resilience amid federal budget continuity.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — March 04, 2026

DHS dominates with $2.28B in mega-contracts for shipbuilding (Bollinger $2.08B, Birdon $106M) and border barriers (BCCG $105M), signaling sustained homeland security capex through 2034. Six bullish signals highlight construction and IT/services momentum, with $3.84B total obligations and $1.0B+ in unexercised options for upside. HHS awards ($337M) provide steady health services funding to 2029, though neutral equity impact from nonprofit recipient.

7 total filings